<

HARDMAN & CO RESEARCH Hardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)

Transparency directive : regulatory news

25/02/2021 08:15

Hardman & Co Research
Hardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)

25-Feb-2021 / 07:15 GMT/BST


Hardman & Co Research: Attention turning to Chronocort(R)

Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is being rolled out by Diurnal throughout Europe and has been launched in the US by its commercial partner, Eton Pharmaceuticals (ETON). The European and UK regulators are currently reviewing the submissions for marketing authorisation for Chronocort, with approval possible in the next month. Also, DITEST now has a clear regulatory pathway, and the development funding in place. Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/attention-turning-to-chronocort/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
1 Frederick's Place
London
EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall

+44 20 3693 7075

 

mh@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1170992  25-Feb-2021 

fncls.ssp?fn=show_t_gif&application_id=1170992&application_name=news&site_id=symex


Other stories

29/03/2024 10:56
29/03/2024 10:08
29/03/2024 12:40
29/03/2024 11:44
29/03/2024 09:30
29/03/2024 10:30
29/03/2024 12:17
29/03/2024 10:54
28/03/2024 16:07
28/03/2024 23:55
29/03/2024 07:00
29/03/2024 11:32
28/03/2024 21:00
29/03/2024 12:03
29/03/2024 09:14
29/03/2024 03:23
29/03/2024 06:20
29/03/2024 11:15
27/03/2024 15:52
27/03/2024 19:23
29/03/2024 04:00
28/03/2024 12:03
29/03/2024 12:13
29/03/2024 13:00
28/03/2024 21:58
29/03/2024 01:27
29/03/2024 12:25
29/03/2024 12:36
29/03/2024 07:21
29/03/2024 07:53
29/03/2024 01:26
27/03/2024 21:46
25/03/2024 11:47
28/03/2024 17:55
29/03/2024 07:00
29/03/2024 00:01
29/03/2024 10:38
28/03/2024 18:22